UCB NORDIC A/S: Financial statements 2012
CVR: 26688949
Source: annual report 2012, Danish Business Authority
01/01/2012 – 31/12/2012
UCB NORDIC A/S (CVR 26688949) has filed annual accounts for 2012. In 2012, the company reported a gross profit of DKK 31,450,000 and a net result of DKK -1,292,000. Equity in the 2012 report amounted to DKK 6,097,000. The solvency ratio was 8.7%. The company had 26 employees in the financial year.
- Gross Profit
- DKK 31,450,000
- Profit/Loss
- DKK -1,292,000
- Equity
- DKK 6,097,000
- Total Assets
- DKK 70,144,000
- Employees
- 26
Official annual report
Keep an eye on UCB NORDIC A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2012
As of February 28, 2012, Jean-Luc Pierre Raymond Moreau has joined the board of directors of UCB NORDIC A/S.
As of February 28, 2012, Philippe Edgar R Vandeput has joined the board of directors of UCB NORDIC A/S.
As of February 28, 2012, Dominique Laurent Vanfleteren has left the board of directors of UCB NORDIC A/S.
As of February 28, 2012, Scott Dunseth Myers has left the board of directors of UCB NORDIC A/S.
About UCB NORDIC A/S
UCB NORDIC A/S is a Danish company of the type Aktieselskab based in København S, founded in 2002. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named UCB NORDICS ApS and CELLTECH NORDIC ApS. The management consists of Mari-Ann Retz. The board consists of Laura Ann Byram (chair), Christina Dyreborg Jeppesen and Jaana Mattila. The company is owned by UCB Pharma SA. The company has 48 employees (2026). In 2025, the company reported a gross profit of DKK 88,278,000 and a net result of DKK 6,014,000 compared with DKK 5,226,000 the year before. Equity in the 2025 report amounted to DKK 18,047,000.